Effect of Cabergoline on Weight and Glucose Tolerance

Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01395602

Enrollment

Registered

2011-07-15

Start date

2002-04-30

Completion date

2011-07-31

Last updated

2015-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Weight, Impaired Glucose Tolerance in Obese

Brief summary

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks. The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Interventions

DRUGCabergoline

cabergoline 0.5 mg twice weekly

OTHERplacebo

1 pill twice weekly

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* age 18 - 55 years * BMI 30 -40

Exclusion criteria

* diabetes, * clinically significant medical condition, * use of medications that effect blood glucose or body weight

Design outcomes

Primary

Measure	Time frame
body weight	16 weeks

Secondary

Measure	Time frame
glucose	16 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026